RxDoctor Payments Data

Lynda Hirakami, APRN

Family · Pahoa, HINPI 1952586752

Payments from drug & device makers

$875in general payments, 2019–2025

Across 41 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$330
  • Lilly USA, LLC$144
  • AbbVie$125
  • Boehringer Ingelheim$112
  • AstraZeneca$60
  • Biohaven Pharmaceuticals, Inc.$44
  • plus $59 from 2 others

What the payments were for

  • Food & beverage$86399%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$875 in reported general payments places this provider in the 70th percentile of 466 family providers in Hawaii.

See all family providers in Hawaii

Medicare billing

Part B allowed, 2024
$27,068
Medicare patients
104
Services billed
312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$88,387
TrulicityDulaglutide33$71,250
JardianceEmpagliflozin30$53,456
EliquisApixaban42$46,324
Aimovig AutoinjectorErenumab-Aooe19$44,314
Soliqua 100-33Insulin Glargine/Lixisenatide17$17,720
VascepaIcosapent Ethyl26$13,627
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$12,288
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,864
Irbesartan182$4,079
Wixela InhubFluticasone Propion/Salmeterol29$3,677
Albuterol Sulfate HfaAlbuterol Sulfate109$2,609
Duloxetine Hcl20$2,058
Omeprazole60$1,948
Quetiapine Fumarate50$1,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$28$88,38791 claims
Lilly USA, LLCTrulicity$144$71,25033 claims
Boehringer IngelheimJardiance$112$53,45630 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$31$17,72017 claims
AbbVieSynthroid$125$1,17620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 466 family providers in Hawaii.

Other family in Pahoa

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →